<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04227808</url>
  </required_header>
  <id_info>
    <org_study_id>HCC-LEN-Adjuvant</org_study_id>
    <nct_id>NCT04227808</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma</brief_title>
  <official_title>Safety and Efficacy of Lenvatinib as an Adjuvant Therapy in Patients With Hepatocellular Carcinoma Following Radical Resection: A Single-Arm and Open-Label Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lenvatinib is the standard of care for patients with advanced hepatocellular carcinoma (HCC).
      The aim of the single-arm, open-label, phase II clinical trial is to evaluate the efficacy
      and safety of lenvatinib as an adjuvant therapy for patients underwent radical resection of
      HCC with a high risk of tumor recurrence.

      Investigator hypothesize that lenvatinib may be an effective adjuvant treatment for HCC, and
      12-month adjuvant treatment with lenvatinib can improve one-year recurrence-free survival
      rate (RFS) of HCC patients after surgical resection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There's no widely accepted adjuvant therapy for patients with HCC. Lenvatinib, a
      multi-targeted tyrosine kinase inhibitor, was approved for advanced or unresectable HCC. In
      this study, investigators aim to evaluate the effects and safety of adjuvant apatinib therapy
      for the patients who underwent curative resection for HCC with high risk of disease
      recurrence.

      Participants who underwent radical resection for HCC with high risk of tumor recurrence will
      be recruited in this study. During 4 to 6 weeks after surgery, each participant will receive
      a screening visit to exclude residual tumors. Each eligible participant will be treated with
      lenvatinib until tumor recurrence, intolerant adverse effect, participant' refusal, or
      completing 12-month treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year RFS rate</measure>
    <time_frame>1 year after LPI</time_frame>
    <description>1-year RFS rate is defined as the percentage of patients who do not experience tumor recurrence or death from any cause after 1-year treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>The duration from the date of first dosage to the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>13 months</time_frame>
    <description>An adverse event (AE) refers to any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, but which does not necessarily have a causal relationship with this treatment. Number and classification of participants with treatment-related adverse events as assessed by CTCAE v4.0 were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events(SAE)</measure>
    <time_frame>13 months</time_frame>
    <description>A serious adverse event (SAE) refers to an event in clinical trials that requires inpatient hospitalization or causes prolongation of existing hospitalization, permanent disability, incapacity, threats to life or death, and birth defect, etc. Number and classification of participants with treatment-related serious adverse events as assessed by CTCAE v4.0 were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>13 months</time_frame>
    <description>Health-related quality of life questionnaire measured by EORTC QLQ-HCC18.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hepatocellular Carcinoma (HCC)</condition>
  <arm_group>
    <arm_group_label>Lenvatinib Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Participants will be given lenvatinib (12 mg/d for body weight≥60kg, 8 mg/d for body weight &lt; 60kg) for 12 months until disease recurrence or intolerance AEs or death.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvima 4 mg Oral Capsule</intervention_name>
    <description>The participants will receive treatment with lenvatinib for 12 months after recruitment or until disease recurrence, intolerance AEs, or death. In case of treatment-related adverse effects, interruption or reduction is allowed.</description>
    <arm_group_label>Lenvatinib Arm</arm_group_label>
    <other_name>Lenvatinib 4 mg Oral Capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients aged 18-75;

          2. Histological diagnosis of HCC;

          3. Tumor stage before surgery: IIb/IIIa stage (&gt;3 tumor nodules, or vascular invasion)
             HCC according to China Liver Cancer Staging System (or BCLC B/C/PVTT);

          4. Underwent R0 resection (microscopic or macroscopic tumor clearance) in four to six
             weeks before recruitment; no residual tumor before recruitment by imaging study
             (MRI/CT), nor metastases to other organs;

          5. Adequate liver, renal functions;

          6. Written informed consent;

          7. ECOG 0-1 and Child-Pugh A.

        Exclusion Criteria:

          1. WBC&lt;4.0*10^9/L, HB&lt;80 g/L, and PLT&lt;75*10^9/L at blood screening;

          2. Coagulation function: (prothrombin time) international normalized ratio (INR) &gt;2.3, or
             extension of prothrombin time&gt;6 seconds;

          3. Liver function: serum albumin (ALB)&lt;2.8 g/dl, total bilirubin (TBIL)&gt;51.3μmol/L,
             alanine aminotransferase and aspartate aminotransferase (ALT and AST)&gt;5 times the
             upper limit of normal range;

          4. Renal function: serum creatinine (Cr)&gt;1.5 times the upper limit of normal range;

          5. lymph node metastases;

          6. The participant has uncontrolled ascites, hepatic encephalopathy, Gilbert's syndrome,
             and sclerosing cholangitis, etc.;

          7. The participant was included in other clinical trials 30 days before the selection;

          8. Other conditions that the investigators considered that not unsuitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Zhou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian Zhou</last_name>
    <phone>0086-21-64041990</phone>
    <email>zhou.jian@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huichuan Sun</last_name>
    <phone>0086-21-64041990</phone>
    <email>sun.huichuan@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lianxin Liu</last_name>
    </contact>
    <contact_backup>
      <last_name>Weidong Jia</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiyong Huang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tianfu Wen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>180 Fenglin Road</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Zhou</last_name>
      <phone>0086-21-64041990</phone>
      <email>zhou.jian@zs-hospital.sh.cn</email>
    </contact>
    <contact_backup>
      <last_name>Huichuan Sun</last_name>
      <phone>0086-21-64041990</phone>
      <email>sun.huichuan@zs-hospital.sh.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Jian Zhou</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huichuan Sun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.</citation>
    <PMID>29433850</PMID>
  </reference>
  <reference>
    <citation>Zhou J, Sun HC, Wang Z, Cong WM, Wang JH, Zeng MS, Yang JM, Bie P, Liu LX, Wen TF, Han GH, Wang MQ, Liu RB, Lu LG, Ren ZG, Chen MS, Zeng ZC, Liang P, Liang CH, Chen M, Yan FH, Wang WP, Ji Y, Cheng WW, Dai CL, Jia WD, Li YM, Li YX, Liang J, Liu TS, Lv GY, Mao YL, Ren WX, Shi HC, Wang WT, Wang XY, Xing BC, Xu JM, Yang JY, Yang YF, Ye SL, Yin ZY, Zhang BH, Zhang SJ, Zhou WP, Zhu JY, Liu R, Shi YH, Xiao YS, Dai Z, Teng GJ, Cai JQ, Wang WL, Dong JH, Li Q, Shen F, Qin SK, Fan J. Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). Liver Cancer. 2018 Sep;7(3):235-260. doi: 10.1159/000488035. Epub 2018 Jun 14.</citation>
    <PMID>30319983</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 5, 2020</study_first_submitted>
  <study_first_submitted_qc>January 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>January 11, 2020</last_update_submitted>
  <last_update_submitted_qc>January 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Jian Zhou</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

